{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:47:16Z","timestamp":1782532036188,"version":"3.54.5"},"reference-count":30,"publisher":"Pharmaceutical Society of Japan","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,6,27]]},"DOI":"10.1248\/bpb.b26-00222","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:12:58Z","timestamp":1782511978000},"page":"1023-1037","source":"Crossref","is-referenced-by-count":0,"title":["An Improved Brain-Penetrating Nanoformulation of the VIPR2 Antagonist Peptide KS-133 for Treating Cognitive Impairment in Schizophrenia"],"prefix":"10.1248","volume":"49","author":[{"given":"Kotaro","family":"Sakamoto","sequence":"first","affiliation":[{"name":"Research &amp; Development Department, Ichimaru Pharcos Co., Ltd., 318\u20131 Asagi, Motosu, Gifu 501\u20130475, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1\u20132\u20133 Kasumi, Minami-ku, Hiroshima 734\u20138553, Japan"},{"name":"Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, The University of Osaka, 1\u20136 Yamadaoka, Suita, Osaka 565\u20130871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Koan","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1\u20132\u20133 Kasumi, Minami-ku, Hiroshima 734\u20138553, Japan"},{"name":"Department of Biological Endodontics, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1\u20132\u20133 Kasumi, Minami-ku, Hiroshima 734\u20138553, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runa","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Research &amp; Development Department, Ichimaru Pharcos Co., Ltd., 318\u20131 Asagi, Motosu, Gifu 501\u20130475, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1\u20132\u20133 Kasumi, Minami-ku, Hiroshima 734\u20138553, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1\u20132\u20133 Kasumi, Minami-ku, Hiroshima 734\u20138553, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Ishimura","sequence":"additional","affiliation":[{"name":"Center for Supporting Drug Discovery and Life Science Research, Graduate School of Pharmaceutical Sciences, The University of Osaka, 1\u20136 Yamadaoka, Suita, Osaka 565\u20130871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Nunomura","sequence":"additional","affiliation":[{"name":"Center for Supporting Drug Discovery and Life Science Research, Graduate School of Pharmaceutical Sciences, The University of Osaka, 1\u20136 Yamadaoka, Suita, Osaka 565\u20130871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangzhong","family":"Lin","sequence":"additional","affiliation":[{"name":"Center for Supporting Drug Discovery and Life Science Research, Graduate School of Pharmaceutical Sciences, The University of Osaka, 1\u20136 Yamadaoka, Suita, Osaka 565\u20130871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Translational Research Center, Hiroshima University, 1\u20132\u20133 Kasumi, Minami-ku, Hiroshima 734\u20138553, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Shiba","sequence":"additional","affiliation":[{"name":"Department of Biological Endodontics, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1\u20132\u20133 Kasumi, Minami-ku, Hiroshima 734\u20138553, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nishizawa","sequence":"additional","affiliation":[{"name":"Chemical Research Laboratories, Nissan Chemical Corporation, 2\u201310\u20131 Tsuboi-Nishi, Funabashi, Chiba 274\u20138507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsaku","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, The University of Osaka, 1\u20136 Yamadaoka, Suita, Osaka 565\u20130871, Japan"},{"name":"Center for Supporting Drug Discovery and Life Science Research, Graduate School of Pharmaceutical Sciences, The University of Osaka, 1\u20136 Yamadaoka, Suita, Osaka 565\u20130871, Japan"},{"name":"Global Center for Medical Engineering and Informatics, The University of Osaka, 2\u20132 Yamadaoka, Suita, Osaka 565\u20130871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Ago","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1\u20132\u20133 Kasumi, Minami-ku, Hiroshima 734\u20138553, Japan"},{"name":"Global Center for Medical Engineering and Informatics, The University of Osaka, 2\u20132 Yamadaoka, Suita, Osaka 565\u20130871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Marder SR, Cannon TD. Schizophrenia. <i>N. Engl. J. Med.<\/i>, <b>381<\/b>, 1753\u20131761 (2019).","DOI":"10.1056\/NEJMra1808803"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. <i>Lancet<\/i>, <b>399<\/b>, 473\u2013486 (2022).","DOI":"10.1016\/S0140-6736(21)01730-X"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Saha KB, Bo L, Zhao S, Xia J, Sampson S, Zaman RU. Chlorpromazine <i>versus<\/i> atypical antipsychotic drugs for schizophrenia. <i>Cochrane Libr.<\/i>, <b>4<\/b>, CD010631 (2016).","DOI":"10.1002\/14651858.CD010631.pub2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. <i>Clin. Ther.<\/i>, <b>32<\/b> (Suppl. 1), S3\u2013S20 (2010).","DOI":"10.1016\/j.clinthera.2010.01.021"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Pisanu C, Severino G, Minelli A, Dierssen M, Potier MC, Fabbri C, Serretti A, Gennarelli M, Baune BT, Squassina A, Baune BT, Squassina A. Biomarkers of treatment-resistant schizophrenia: a systematic review. <i>Neurosci. Appl.<\/i>, <b>3<\/b>, 104059 (2024).","DOI":"10.1016\/j.nsa.2024.104059"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Peitl V, Pulji\u0107 A, \u0160krobo M, Nadalin S, Fumi\u0107 Dunki\u0107 L, Karlovi\u0107 D. Clozapine in treatment-resistant schizophrenia and its augmentation with electroconvulsive therapy in ultra-treatment-resistant schizophrenia. <i>Biomedicines<\/i>, <b>11<\/b>, 1072 (2023).","DOI":"10.3390\/biomedicines11041072"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Levinson DF, Duan J, Oh S, <i>et al<\/i>. Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. <i>Am. J. Psychiatry<\/i>, <b>168<\/b>, 302\u2013316 (2011).","DOI":"10.1176\/appi.ajp.2010.10060876"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Vacic V, McCarthy S, Malhotra D, <i>et al<\/i>. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. <i>Nature<\/i>, <b>471<\/b>, 499\u2013503 (2011).","DOI":"10.1038\/nature09884"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Yuan J, Jin C, Sha W, Zhou Z, Zhang F, Wang M, Wang J, Li J, Feng X, Yu S, Wang J. A competitive PCR assay confirms the association of a copy number variation in the VIPR2 gene with schizophrenia in Han Chinese. <i>Schizophr. Res.<\/i>, <b>156<\/b>, 66\u201370 (2014).","DOI":"10.1016\/j.schres.2014.04.004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ago Y, Condro MC, Tan YV, Ghiani CA, Colwell CS, Cushman JD, Fanselow MS, Hashimoto H, Waschek JA. Reductions in synaptic proteins and selective alteration of prepulse inhibition in male C57BL\/6 mice after postnatal administration of a VIP receptor (<i>VIPR2<\/i>) agonist. <i>Psychopharmacology<\/i>, <b>232<\/b>, 2181\u20132189 (2015).","DOI":"10.1007\/s00213-014-3848-z"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Li Z, Chen J, Xu Y, <i>et al<\/i>. Genome-wide analysis of the role of copy number variation in schizophrenia risk in Chinese. <i>Biol. Psychiatry<\/i>, <b>80<\/b>, 331\u2013337 (2016).","DOI":"10.1016\/j.biopsych.2015.11.012"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Firouzabadi SG, Kariminejad R, Vameghi R, Darvish H, Ghaedi H, Banihashemi S, Firouzkouhi Moghaddam M, Jamali P, Mofidi Tehrani HF, Dehghani H, Narooie-Nejad M, Jamshidi J, Tafakhori A, Sadabadi S, Najmabadi H, Behjati F. Copy number variants in patients with autism and additional clinical features: report of VIPR2 duplication and a novel microduplication syndrome. <i>Mol. Neurobiol.<\/i>, <b>54<\/b>, 7019\u20137027 (2017).","DOI":"10.1007\/s12035-016-0202-y"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Sakamoto K, Chen L, Miyaoka T, Yamada M, Masutani T, Ishimoto K, Hino N, Nakagawa S, Asano S, Ago Y. Generation of KS-133 as a novel bicyclic peptide with a potent and selective VIPR2 antagonist activity that counteracts cognitive decline in a mouse model of psychiatric disorders. <i>Front. Pharmacol.<\/i>, <b>12<\/b>, 751587 (2021).","DOI":"10.3389\/fphar.2021.751587"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Asano S, Yamasaka M, Ozasa K, Sakamoto K, Hayata-Takano A, Nakazawa T, Hashimoto H, Waschek JA, Ago Y. Vasoactive intestinal peptide-VIPR2 signaling regulates tumor cell migration. <i>Front. Oncol.<\/i>, <b>12<\/b>, 852358 (2022).","DOI":"10.3389\/fonc.2022.852358"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Asano S, Ono A, Sakamoto K, Hayata-Takano A, Nakazawa T, Tanimoto K, Hashimoto H, Ago Y. Vasoactive intestinal peptide receptor 2 signaling promotes breast cancer cell proliferation by enhancing the ERK pathway. <i>Peptides<\/i>, <b>161<\/b>, 170940 (2023).","DOI":"10.1016\/j.peptides.2023.170940"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Asano S, Ono A, Baba K, Uehara T, Sakamoto K, Hayata-Takano A, Nakazawa T, Yanamoto S, Tanimoto K, Hashimoto H, Ago Y. Blockade of vasoactive intestinal peptide receptor 2 (VIPR2) signaling suppresses cyclin D1-dependent cell-cycle progression in MCF-7 cells. <i>J. Pharmacol. Sci.<\/i>, <b>154<\/b>, 139\u2013147 (2024).","DOI":"10.1016\/j.jphs.2024.01.002"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Sakamoto K, Kittikulsuth W, Miyako E, Steeve A, Ishimura R, Nakagawa S, Ago Y, Nishiyama A. The VIPR2-selective antagonist KS-133 changes macrophage polarization and exerts potent anti-tumor effects as a single agent and in combination with an anti-PD-1 antibody. <i>PLOS ONE<\/i>, <b>18<\/b>, e0286651 (2023).","DOI":"10.1371\/journal.pone.0286651"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Sakamoto K, Nishiyama T, Miyako E. KS-133\/KS-487 nanoparticles exhibit potent antitumor effects through synergistic LRP1 targeting and VIPR2 inhibition: therapeutic nanoarchitectonics for solid tumors. <i>Adv. Ther.<\/i>, <b>7<\/b>, 2400278 (2024).","DOI":"10.1002\/adtp.202400278"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Ohtsuki S, Uchida Y, Kubo Y, Terasaki T. Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. <i>J. Pharm. Sci.<\/i>, <b>100<\/b>, 3547\u20133559 (2011).","DOI":"10.1002\/jps.22612"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Sakamoto K. Generation of KS-487 as a novel LRP1-binding cyclic peptide with higher affinity, higher stability and BBB permeability. <i>Biochem. Biophys. Rep.<\/i>, <b>32<\/b>, 101367 (2022).","DOI":"10.1016\/j.bbrep.2022.101367"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Sakamoto K, Iwata S, Jin Z, Chen L, Miyaoka T, Yamada M, Katahira K, Yokoyama R, Ono A, Asano S, Tanimoto K, Ishimura R, Nakagawa S, Hirokawa T, Ago Y, Miyako E. Cyclic peptides KS-133 and KS-487 multifunctionalized nanoparticles enable efficient brain targeting for treating schizophrenia. <i>JACS Au<\/i>, <b>4<\/b>, 2811\u20132817 (2024).","DOI":"10.1021\/jacsau.4c00311"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. Animal research: reporting <i>in vivo<\/i> experiments: the ARRIVE guidelines. <i>Br. J. Pharmacol.<\/i>, <b>160<\/b>, 1577\u20131579 (2010).","DOI":"10.1111\/j.1476-5381.2010.00872.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) McGrath JC, Lilley E. Implementing guidelines on reporting research using animals (ARRIVE <i>etc<\/i>.): new requirements for publication in BJP. <i>Br. J. Pharmacol.<\/i>, <b>172<\/b>, 3189\u20133193 (2015).","DOI":"10.1111\/bph.12955"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Huisgen R. 1,3-Dipolar cycloadditions. Past and future. <i>Angew. Chem. Int. Ed.<\/i>, <b>2<\/b>, 565\u2013598 (1963).","DOI":"10.1002\/anie.196305651"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Suys EJA, Warren DB, Pham AC, Nowell CJ, Clulow AJ, Benameur H, Porter CJH, Pouton CW, Chalmers DK. A nonionic polyethylene oxide (PEO) surfactant model: experimental and molecular dynamics studies of Kolliphor EL. <i>J. Pharm. Sci.<\/i>, <b>108<\/b>, 193\u2013204 (2019).","DOI":"10.1016\/j.xphs.2018.11.028"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Jadhav SR, Bryant G, Mata JP, Eldridge DS, Palombo EA, Harding IH, Shah RM. Structural aspects of a self-emulsifying multifunctional amphiphilic excipient: Part II. The case of Cremophor EL. <i>J. Mol. Liq.<\/i>, <b>344<\/b>, 117881 (2021).","DOI":"10.1016\/j.molliq.2021.117881"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Kroll P, Benke J, Enders S, Brandenbusch C, Sadowski G. Influence of temperature and concentration on the self-assembly of nonionic C<sub>i<\/sub>E<sub>j<\/sub> surfactants: a light scattering study. <i>ACS Omega<\/i>, <b>7<\/b>, 7057\u20137065 (2022).","DOI":"10.1021\/acsomega.1c06766"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) McCormack PL. Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus. <i>Drugs<\/i>, <b>74<\/b>, 325\u2013351 (2014).","DOI":"10.1007\/s40265-013-0172-6"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Moniem I, Kafetzopoulos V. Sex differences in schizophrenia: symptomatology, treatment efficacy and adverse effects. <i>Front. Psychiatry<\/i>, <b>16<\/b>, 1594334 (2025).","DOI":"10.3389\/fpsyt.2025.1594334"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Huang Y, Li Y, Pan H, Han L. Global, regional, and national burden of neurological disorders in 204 countries and territories worldwide. <i>J. Glob. Health<\/i>, <b>13<\/b>, 04160 (2023).","DOI":"10.7189\/jogh.13.04160"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/6\/49_b26-00222\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:24:51Z","timestamp":1782530691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/6\/49_b26-00222\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00222","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"article-number":"b26-00222"}}